In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to two ketolides (HMR 3004 and HMR 3647), four macrolides (azithromycin, clarithromycin, erythromycin A, and roxithromycin), and two ansamycins (rifampin and rifapentine).
When tested by agar dilution on Mueller-Hinton agar supplemented with 5% horse blood, the ketolides HMR 3004 and HMR 3647 were slightly more active (MIC at which 90% of the isolates were inhibited [MIC90], 0.03 microg/ml) against Bordetella pertussis than azithromycin, clarithromycin, erythromycin A, and roxithromycin. Azithromycin (MIC90, 0.06 microg/ml) was the most active compound against B. parapertussis. Rifampin and rifapentine were considerably less active.
Hoppe
J E
JE
University Children's Hospital, Tübingen, Germany.
Bryskier
A
A
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D017963:Azithromycin / Q000494:pharmacology; D001884:Bordetella / Q000187:drug effects*; D001886:Bordetella pertussis / Q000187:drug effects*; D017291:Clarithromycin / Q000494:pharmacology; D004917:Erythromycin / Q000494:pharmacology; D048628:Ketolides; D018942:Macrolides; D008826:Microbial Sensitivity Tests; D017828:Rifabutin / Q000031:analogs & derivatives* / Q000494:pharmacology*; D012293:Rifampin / Q000031:analogs & derivatives / Q000494:pharmacology; D015575:Roxithromycin / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D048628:Ketolides; D018942:Macrolides; C105420:RU 64004; D017828:Rifabutin; D015575:Roxithromycin; D004917:Erythromycin; D017963:Azithromycin; D017291:Clarithromycin; C106791:telithromycin; D012293:Rifampin; C018421:rifapentine